Intravenous Immunoglobulins in Severe and Refractory Solar Urticaria
NCT ID: NCT01360658
Last Updated: 2013-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
10 participants
INTERVENTIONAL
2011-06-30
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Omalizumab in Severe and Refractory Solar Urticaria
NCT02262130
Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment
NCT02550106
Efficacy Study of Omalizumab in Cholinergic Urticaria
NCT02012387
Effect of Anti-IgE in Chronic Urticaria
NCT00130234
Phase II Solar Urticaria (SU) Pilot Study
NCT00859534
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intravenous immunoglobulins
Intravenous immunoglobulins
Intravenous immunoglobulins
Single administration of 2 g/kg intravenous immunoglobulins over 2 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intravenous immunoglobulins
Single administration of 2 g/kg intravenous immunoglobulins over 2 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* signed informed consent
* solar urticaria (SU) confirmed with photoexplorations
* SU involving the face or generalized to the whole body or accompanied with bronchospasm or triggered by artificial light or per annual SU
* SU with altered quality of life
* SU resistant to photoprotection
* SU resistant to the association of two different antihistaminics during 3 months
Exclusion Criteria
* Heat triggered urticaria
* Contra-indications to IVIG
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health, France
OTHER_GOV
Saint-Louis Hospital, Paris, France
OTHER
Centre Hospitalier Universitaire de Besancon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
François Aubin, Pr
Role: PRINCIPAL_INVESTIGATOR
University Hospital of Besançon
Manuelle Viguier, Dr
Role: PRINCIPAL_INVESTIGATOR
Saint-Louis Hospital, Paris, France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Regional University Hospital
Besançon, , France
University Hospital
Caen, , France
University Hospital
Grenoble, , France
Regional University Hospital
Lille, , France
University hospital
Limoges, , France
Regional University Hospital
Montpellier, , France
University Hospital
Nancy, , France
University Hospital
Nîmes, , France
Saint louis Hospital
Paris, , France
University Hospital
Reims, , France
University Hospital
Rennes, , France
University Hospital
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N/2010/57
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.